Home / Business / A DARPA-funded implantable biochip to detect COVID-19 could hit markets in 2021

A DARPA-funded implantable biochip to detect COVID-19 could hit markets in 2021



Tthe most important scientific discovery since gravity has been hidden in clear vision for almost a decade and its destructive potential for humanity is so enormous that the largest war machine on the planet immediately used its vast resources to own and control it, funding its research and development through organs such as the National Institutes of Health (NIH), the Defense Advanced Research Projects Agency (DARPA) and HHS ‘BARDA.

The revolutionary breakthrough came to a Canadian researcher named Derek Rossi in 2010 by mistake. The now retired Harvard professor claimed in an interview with National Post that he found a way to “reprogram”

; the molecules that carry the genetic instructions for cell development in the human body, not to mention all biological life forms.

These molecules are called ‘messenger ribonucleic acid’ or mRNA and the newfound ability to rewrite these instructions to produce some form of cell in a biological organism has radically changed Western medicine and science, although no one has noticed it yet. As Rossi, himself, puts it: “The really important discovery here was that you could now use mRNA, and if you got it in the cells, you could get mRNA to express any protein in the cells, and this was the big thing. . ”

It was so large that Rossi was able to retire in 2014 after the company he founded with Flagship Pioneering private equity firm to leverage his innovation, – Modern Inc., attracted nearly half a billion dollars in federal prize money to start developing vaccines using the technique. Rossi is no longer affiliated with Moderna beyond his shareholding, but only “watches what happens next” and if he is anything like the spotted “hockey dad” he is imagined to be, he must be terrified.

Remote control biology

As early as 2006, DARPA already investigated how to identify viral, upper respiratory pathogens through the Health and Disease Prediction Program (PHD), which led to the creation of the Office’s Biological Technologies Office (BTO), reported by Whitney Webb in a May article for The Last American Vagabond. In 2014, DARPA’s BTO launched its “In Vivo Nanoplatforms” (IVN) program, which researches implantable nanotechnologies, leading to the development of “hydrogel”.

Hydrogel is a nanotechnology whose inventors early boasted that “If [it] with FDA approval, consumers could then have the sensors implanted in their core to measure their levels of glucose, oxygen and lactate. This contact lens-like material requires the insertion of a special injector under the skin where it can transmit light-based digital signals over a 5G wireless network.

hydrogel Penny

A penny aside a 3D-printed hydrogel model of a lung-emitting airbag in Rice University’s Houston BRC laboratory. Melissa Phillip | Houston Chronicle via AP

Once implanted inside the body, human cells are transmitted to all mRNA programs delivered via this substrate, releasing a nightmare of possibilities. This is perhaps the first true step towards complete transhumanism; a “philosophy” that is fashionable among many powerful and influential people, such as Google’s Ray Kurzweil and Eric Schmidt, and whose proponents see the fusion of technology and biology as an inevitable consequence of human development.

The private company created to market this technology, which enables remote control of biological processes and opens the door to the potential manipulation of our biological responses and ultimately our entire existence is called Profusa Inc and its operations are funded by millions from NIH and DARPA. In March, the company was quietly introduced in the cramped base COVID-19 in March 2020, when it announced an injectable biochip for detecting viral respiratory diseases, including COVID-19.

A wholly owned subsidiary

In July, a preliminary report funded by Fauci’s NIAID and NIH on an mRNA vaccine against SARS-CoV-2 was published in New England Journal of Medicine, concluded that the mRNA-1273 vaccine. provided by Moderna for the study, “induced anti-SARS-CoV-2 immune response in all participants, and no experimental safety concerns were identified”, and supported “further development of this vaccine.”

One month earlier, the NIH had claimed a joint stake in Modern’s mRNA COVID-19 vaccine, citing a contract signed in December 2019, which stated that “mRNA coronavirus vaccine candidates [are] developed and jointly owned ”by both parties. Modern disputes the position of the federal government, saying that the company “has a broadly owned and licensed IP property” and is “not aware of any IP that would prevent us from commercializing our product candidates, including mRNA-1273.”

A poster seeking volunteers to participate in a COVID-19 vaccine study by NIH and Modern Inc., July 27, 2020, in Binghamton, NY Hans Pennink | AP

The only obstacle is a delivery system that, despite Moderna’s claims to be developed separately, is unlikely to receive FDA approval before the federal government’s own DARPA-developed hydrogel technology, combined with Profusa’s DARPA-funded light sensor technology, which is expected to receive rapid approvals. from the Food and Drug Administration in early 2021 and, more than likely, used to distribute a coronavirus vaccine with the capacity to literally alter our DNA.

In addition, the Department of Health and Human Services (HHS) is currently examining Moderna’s patent applications and claims that it failed to disclose “federal government support” in its COVID vaccine candidate patent applications, according to law. The technology could lead to the federal government owning a 100 percent stake in mRNA-1273.

Function photo | Jowan Osterlund from Biohax Sweden has a small microchip implant, similar to the one implanted in workers at Epicenter digital innovation operations in central Stockholm. James Brooks | AP

Raul Diego is a MintPress News Staff Writer, independent photojournalist, researcher, author and documentary filmmaker.